Ascendis Launches YUVIWEL in U.S., Secures Orphan Drug Exclusivity
Event summary
- Ascendis Pharma's YUVIWEL (navepegritide) received orphan drug exclusivity from the U.S. FDA for treating achondroplasia in pediatric patients.
- YUVIWEL is now commercially available in the U.S., with revenue recognition beginning following patient approvals and therapy initiation.
- The orphan drug exclusivity for YUVIWEL will run through February 27, 2033.
- YUVIWEL is the first and only once-weekly treatment approved by the FDA for increasing linear growth in children with achondroplasia.
The big picture
Ascendis Pharma's launch of YUVIWEL marks a significant milestone in the treatment of achondroplasia, a rare genetic condition affecting over 250,000 people worldwide. The orphan drug exclusivity and commercial availability in the U.S. position Ascendis as a leader in growth disorders, with potential to expand its portfolio of TransCon-based therapies. The strategic focus on rare diseases and innovative drug delivery technologies aligns with broader industry trends toward specialized treatments for underserved patient populations.
What we're watching
- Revenue Trajectory
- How quickly Ascendis can scale YUVIWEL's commercial adoption and revenue growth in the U.S. market.
- Regulatory Milestones
- Whether Ascendis can successfully verify and describe clinical benefits in confirmatory trials to maintain FDA approval.
- Competitive Positioning
- The pace at which Ascendis can leverage its TransCon technology platform to develop additional best-in-class therapies.
Related topics